Investigation on Medication Status in Patients with Systemic Lupus Erythematosus in 109 Medical Institutions from 9 Cities in China from 2016 to 2020

doi:10.14009/j.issn.1672-2124.2022.08.024

您当前的位置：

首页 >

文章列表页 >

Investigation on Medication Status in Patients with Systemic Lupus Erythematosus in 109 Medical Institutions from 9 Cities in China from 2016 to 2020

更新时间：2023-04-16

- Investigation on Medication Status in Patients with Systemic Lupus Erythematosus in 109 Medical Institutions from 9 Cities in China from 2016 to 2020
- Vol. 22, Issue 8, Pages: 1005-1009(2022)
- 作者机构：
  
  1. 北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院)
  2. 北京大学人民医院药剂科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.08.024
  CLC： R593.241
- Published：2022，
扫描看全文
Investigation on Medication Status in Patients with Systemic Lupus Erythematosus in 109 Medical Institutions from 9 Cities in China from 2016 to 2020. [J]. 22(8):1005-1009(2022)
DOI：

Investigation on Medication Status in Patients with Systemic Lupus Erythematosus in 109 Medical Institutions from 9 Cities in China from 2016 to 2020. [J]. 22(8):1005-1009(2022) DOI： 10.14009/j.issn.1672-2124.2022.08.024.

摘要

目的：了解我国9个城市系统性红斑狼疮(SLE)患者门急诊处方药物应用情况，并给出合理化建议，以期为临床合理用药提供参考。方法：收集2016—2020年北京、成都和广州等9个城市109家样本医疗卫生机构按季度随机抽取的全部免疫用药处方，对患者用药情况进行分析。计算治疗SLE药物的用药频度(DDDs)、限定日费用(DDC)和销售金额增长率等，进而分析其临床应用情况。结果：本研究共纳入480 886张处方。统计结果显示，SLE患者年龄主要集中于>20～40岁(222 492人次);女性患者(412 894人次)明显多于男性患者(47 373人次)。2016—2020年，9个城市SLE患者治疗药物的总销售金额一直稳步增长，销售金额最高的药品为吗替麦考酚酯；DDDs最高的药品为泼尼松，其次为羟氯喹，且泼尼松的DDDs在2016—2019年逐年增长(2020年有所降低)

羟氯喹的DDDs在5年来逐年增长。结论：2016—2020年我国9个城市SLE患者的治疗药物总销售金额呈升高趋势；各城市SLE症患者的药物使用情况虽有所差异，但总体上符合指南推荐用药；同时，应对个别药物的安全性多加关注。

Abstract

OBJECTIVE: To investigate the medication on patients with systemic lupus erythematosus（SLE） in outpatient and emergency prescriptions in 9 cities in China

and propose reasonable suggestions

so as to provide reference for clinical rational drug use. METHODS: All the prescriptions of immunization drugs were randomly selected by quarter from 109 sample medical institutions in 9 cities including Beijing

Chengdu and Guangzhou from 2016 to 2020

the medication of patients were collected and analyzed. The defined daily dose（DDDs）

defined daily cost（DDC） and growth rate of consumption sum of drugs for SLE were calculated

and then analyzed for the clinical application. RESULTS: A total of 480 886 prescriptions were enrolled in this study. The statistical results showed that the age of SLE patients was mainly >20 to 40 years old（222 492 person-times）; there were more female patients（412 894 person-times） than male patients（47 373 person-times）. From 2016 to 2020

the total consumption sum of drugs for SLE patients in 9 cities increased steadily

and the drug with the highest consumption sum was mycophenolate mofetil; the drug with the highest DDDs was prednisone

followed by hydroxychloroquine

and the DDDs of prednisone increased year by year from 2016 to 2019（decreased in 2020）

the DDDs of hydroxychloroquine increased year by year for the 5 years. CONCLUSIONS: The total consumption sum of therapeutic drugs for SLE patients in 9 cities in China from 2016 to 2020 shows an increasing trend; although the medication on SLE patients varies from each city

it is generally in line with the guideline recommended drug use; meanwhile

more attention should be paid to the safety of individual drugs.

关键词

系统性红斑狼疮治疗药物销售金额限定日剂量

Keywords

Systemic lupus erythematosusTherapeutic drugsConsumption sumDefined daily dose

references

查看原文

Views

126

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Recommendations and Evidence for COVID-19 Vaccine in Patients with Systemic Lupus Erythematosus

Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020

Investigation and Analysis of Application of Tamoxifen and Toremifene in the Treatment of Breast Cancer in 15 Grade Ⅲ,Level A Hospitals in Shanghai from 2015 to 2019

Analysis of Application of Hospital Preparations in Sichuan Provincial People’s Hospital from 2017 to 2019

Analysis of Clinical Application and Management Mode of Antibiotics in A Grade Ⅲ,Level A Hospital in Ningxia

Related Author

TONG Rongsheng

YANG Qianwen

ZHU Yuyan

HE Xia

PENG Kun

WU Yue

LIU Xinxia

DU Shan

Related Institution

Dept.of Nephrology, Affiliated Hospital of University of Electronic Science and Technology of China·Sichuan Provincial People’s Hospital

School of Medicine, University of Electronic Science and Technology of China/Sichuan Provincial Key Laboratory of Individualized Drug Therapy

Dept.of Pharmacy, Affiliated Hospital of University of Electronic Science and Technology of China·Sichuan Provincial People’s Hospital

School of Medicine, University of Electronic Science and Technology of China

Dept.of Pharmacy,the First Affiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital

⁰